Justia Antitrust & Trade Regulation Opinion Summaries

The case involved a dispute between Winn-Dixie Stores and the Eastern Mushroom Marketing Cooperative, Inc. (EMMC), its individual mushroom farmer members, and certain downstream distributors. Winn-Dixie accused the defendants of violating antitrust laws by engaging in a price-fixing agreement. The U.S. Court of Appeals for the Third Circuit held that the District Court was correct in applying the rule of reason, rather than a "quick-look" review, in assessing the legality of the defendants' pricing policy under the Sherman Act. The court found that the complex and variable nature of the arrangements within the cooperative, involving both horizontal and vertical components, necessitated a careful analysis to determine anticompetitive effects. The court also held that the jury's verdict, which found that the defendants' pricing policy did not harm competition, was not against the weight of the evidence and did not warrant a new trial. The court affirmed the District Court’s judgment in favor of the defendants. View "Winn Dixie Stores v. Eastern Mushroom Marketing Cooperative Inc" on Justia Law

In this case, a group of California wholesale businesses, the plaintiffs, brought a lawsuit against Innovation Ventures, LLC, and Living Essentials, LLC, the defendants, under the Robinson-Patman Price Discrimination Act. The plaintiffs accused the defendants of offering less favorable pricing, discounts, and reimbursements to them than to the Costco Wholesale Corporation for the sale of 5-hour Energy drink. The United States Court of Appeals for the Ninth Circuit affirmed in part and reversed in part the district court’s judgment.The court held that the district court did not abuse its discretion in instructing the jury that the plaintiffs needed to show that Living Essentials made “reasonably contemporaneous” sales to them and to Costco at different prices and that the price discrimination was not justified by functional discounts compensating Costco for marketing or promotional functions. The court concluded that the functional discount doctrine was available to the defendants, regardless of whether the plaintiffs and Living Essentials were on the same level in the distribution chain.However, the court vacated the district court's ruling on the plaintiffs' claim for injunctive relief under section 2(d) of the Robinson-Patman Act. This section prohibits a seller from providing anything of value to one customer unless it is available on proportionally equal terms to all other competing customers. The court found that the district court committed legal and factual errors in determining that Costco and the plaintiffs operated at different functional levels and therefore competed for different customers of 5-hour Energy. The case was remanded for the district court to reconsider whether Costco and the plaintiffs purchased 5-hour Energy from Living Essentials within approximately the same period of time, or if the plaintiffs were otherwise able to prove competition. View "U.S. WHOLESALE OUTLET & DISTR. V. INNOVATION VENTURES, LLC" on Justia Law

In 2020, Illumina, a for-profit corporation that manufactures and sells next-generation sequencing (NGS) platforms, which are crucial tools for DNA sequencing, entered into an agreement to acquire Grail, a company it had initially founded and then spun off as a separate entity in 2016. Grail specializes in developing multi-cancer early detection (MCED) tests, which are designed to identify various types of cancer from a single blood sample. Illumina's acquisition of Grail was seen as a significant step toward bringing Grail’s developed MCED test, Galleri, to market.However, the Federal Trade Commission (FTC) objected to the acquisition, arguing that it violated Section 7 of the Clayton Act, which prohibits mergers and acquisitions that may substantially lessen competition. The FTC contended that because all MCED tests, including those still in development, relied on Illumina’s NGS platforms, the merger would potentially give Illumina the ability and incentive to foreclose Grail’s rivals from the MCED test market.Illumina responded by creating a standardized supply contract, known as the "Open Offer," which guaranteed that it would provide its NGS platforms to all for-profit U.S. oncology customers at the same price and with the same access to services and products as Grail. Despite this, the FTC ordered the merger to be unwound.On appeal, the United States Court of Appeals for the Fifth Circuit found that the FTC had applied an erroneous legal standard in evaluating the impact of the Open Offer. The court ruled that the FTC should have considered the Open Offer at the liability stage of its analysis, rather than as a remedy following a finding of liability. Furthermore, the court determined that to rebut the FTC's prima facie case, Illumina was not required to show that the Open Offer would completely negate the anticompetitive effects of the merger, but rather that it would mitigate these effects to a degree that the merger was no longer likely to substantially lessen competition.The court concluded that substantial evidence supported the FTC’s conclusions regarding the likely substantial lessening of competition and the lack of cognizable efficiencies to rebut the anticompetitive effects of the merger. However, given its finding that the FTC had applied an incorrect standard in evaluating the Open Offer, the court vacated the FTC’s order and remanded the case for further consideration of the Open Offer's impact under the proper standard. View "Illumina v. FTC" on Justia Law

In the case before the United States Court of Appeals for the Fourth Circuit, the defendant, Brent Brewbaker, appealed from his conviction of a per se antitrust violation under § 1 of the Sherman Act, as well as five counts of mail and wire fraud. Brewbaker had asked the district court to dismiss the Sherman Act count for failure to state an offense, but the court denied his motion. The court of appeals reversed Brewbaker’s Sherman Act conviction, finding that the indictment failed to state a per se antitrust offense as it purported to do. The court, however, affirmed his fraud convictions and remanded the case for resentencing.The legal basis for the case was Brewbaker's argument that the indictment should have been dismissed because it did not state a per se Sherman Act offense, a claim that the appellate court agreed with. The court explained that the indictment alleged a restraint that was both horizontal and vertical in nature, which does not fit neatly into either category as per existing case law. The court further noted that the Supreme Court had not yet clarified how to analyze an agreement between two parties with both vertical and horizontal aspects. The court concluded that the indictment did not allege a restraint that has been previously held to be per se illegal, nor one that economics showed would invariably lead to anticompetitive effects, and thus failed to state a per se violation of the Sherman Act.The court also rejected Brewbaker's claim that the jury instructions on the Sherman Act count "infected" the jury’s consideration of the fraud counts, noting that the fraud counts were not dependent on finding Brewbaker guilty under the Sherman Act. It further cited the presumption that juries follow instructions, and found no extraordinary situation to overcome this presumption. Therefore, the fraud convictions were affirmed. View "US v. Brent Brewbaker" on Justia Law

The Supreme Court reversed the order of the district court concluding that the claims against Appellant did not fall within the categories of claims subject to Nevada's anti-SLAPP statutes without further analysis, holding that remand was required.In the underlying lawsuit, TMM, Inc. (TMMI) filed a third-party complaint against Appellant asserting claims for trade libel, misappropriation of trade secrets, conversion, injunctive relief, abuse of process, and alter ego liability. Appellant filed an anti-SLAPP special motion to dismiss, which the district court denied. The Supreme Court reversed and remanded the case for further proceedings, holding (1) the district court erred in finding that the subject claims did not fall within the categories of claims subject to the anti-SLAPP statute; (2) Appellant met his burden under the first prong of the anti-SLAPP analysis; and (3) the district court applied an incorrect standard in evaluating TMMI's claims under the second prong of the anti-SLAPP analysis. View "Panik v. TMM, Inc." on Justia Law

BioCorRx, Inc. (BioCorRx) was a publicly traded company primarily engaged in the business of providing addiction treatment services and related medication. It issued several press releases that allegedly made misrepresentations and improperly disclosed confidential information about a treatment it was developing for opioid overdose. VDM Biochemicals, Inc. (VDM) specializes in the synthesis and distribution of chemicals, reagents, and other specialty products for life science research. It owned a patent (the patent) for VDM-001, a compound with potential use as a treatment for opioid overdose. In September 2018, VDM and BioCorRx entered into a Mutual Nondisclosure & Confidentiality Agreement (the NDA), which restricted each party’s disclosure of confidential information as they discussed forming a business relationship. A month later, VDM and BioCorRx signed a Letter of Intent to Enter Definitive Agreement to Acquire Stake in Intellectual Property (the letter of intent). The letter of intent memorialized the parties’ shared desire whereby BioCorRx would partner with VDM to develop and commercialize VDM-001. BioCorRx and VDM never signed a formal contract concerning VDM-001. Their relationship eventually soured. BioCorRx filed a complaint (the complaint) against VDM; VDM cross-complained. In response, BioCorRx filed the anti-SLAPP motion at issue here, seeking to strike all the allegations from the cross-complaint concerning the press releases. The Court of Appeal found these statements fell within the commercial speech exemption of California's Code of Civil Procedure section 425.16 (the anti-SLAPP statute) because they were representations about BioCorRx’s business operations that were made to investors to promote its goods and services through the sale of its securities. Since these statements were not protected by the anti-SLAPP statute, the Court reversed the part of the trial court’s order granting the anti-SLAPP motion as to the press releases. The Court affirmed the unchallenged portion of the order striking unrelated allegations. View "BioCorRx, Inc. v. VDM Biochemicals, Inc." on Justia Law

Plaintiff Armadillo Hotel Group, LLC (“Armadillo”) is a buyer and operator of modular and mobile structures throughout North America. According to Armadillo, Defendants Todd Harris and Jason McDaniel were hired in May 2019 to oversee Armadillo’s construction operations and its hotel, food, and beverage operations, respectively. McDaniel resigned in January 2021, Harris in July 2021. Harris and McDaniel asserted that they entered employment agreements with AHG Management as part of the joint venture, but AHG Management breached these agreements by failing to pay the agreed-upon salary, bonuses, and profit-sharing interests. They asserted claims of fraudulent inducement, negligent misrepresentation, tortious interference, and unjust enrichment. Harris, McDaniel, SDRS, and BMC moved to dismiss under Federal Rule of Civil Procedure 12(b)(6) for failure to state a claim. The district court granted the non-GML defendants’ motion to dismiss with prejudice.   The Fifth Circuit reversed. The court explained that it could not find sufficient information in the record to decide if Armadillo and AHG Management were in privity with each other. The fact that the same attorneys filed AHG Management’s amended state counterclaim and Armadillo’s federal complaint is insufficient to show privity. Accordingly, the court found that the district court did not have sufficient information or even assertions about the relationship of Armadillo and AHG Management to perform such an assessment. View "Armadillo Hotel v. Harris" on Justia Law

The Supreme Court affirmed the opinion of the court of appeals affirming the decision of the trial court to grant summary judgment in favor of Defendants in this complaint alleging misappropriation of trade secrets, tortious interference with business contacts, tortious interference with business relationships, and conversion, holding that there was no error.Plaintiff, Hanneman Family Funeral Home and Crematorium, purchased a funeral home but did not retain the funeral home's director, Patrick Orians. Orians accepted employment at another funeral home, Chiles-Laman Funeral & Cremation Services, and used Plaintiff's customer information to solicit business for Chiles-Laman. Plaintiff sued Orians and Chiles-Laman (collectively, Defendants). The trial court entered summary judgment in favor of Defendants, and the court of appeals affirmed. The Supreme Court affirmed, holding (1) the information at issue was not protected by the Ohio Uniform Trade Secrets Act as a trade secret; and (2) Plaintiff's tort claims were preempted by the Ohio Uniform Trade Secrets Act. View "Hanneman Family Funeral Home & Crematorium v. Orians" on Justia Law

The Supreme Court affirmed the judgment of the trial court awarding damages to Companions and Homemakers, Inc. for tortious interference with contractual and business relations and a violation of the Connecticut Unfair Trade Practices Act (CUTPA), Conn. Gen. Stat. 42-110a et seq., holding that A&B Homecare Solutions, LLC was not entitled to relief on its allegations of error.Companions, the largest provide of Medicaid and state-funded home care services in Connecticut, brought this action against A&B. Following a jury trial, the trial court rendered judgment for Companions. The Supreme Court affirmed, holding (1) the trial court did not err in finding that A&B's misrepresentations were tortious; (2) the evidence was sufficient to establish that A&B's allegedly tortious interference cause Companions to suffer damages; and (3) the trial court did not err in finding that A&B's conduct was a violation of CUTPA. View "Companions & Homemakers, Inc. v. A&B Homecare Solutions" on Justia Law

Septic systems comprise a septic tank that isolates and contains the sewage; the remaining wastewater flows through a drain field, where microorganisms treat it. Customers have two options for private septic systems—aerobic treatment units (contained systems), or soil-based/open-bottom treatment systems (T&D systems). Geomatrix markets and sells a T&D system, while many of its competitors sell contained systems.Since 1970, NSF has offered certification for the wastewater treatment industry, A manufacturer needs to obtain certification before marketing products in at least 37 states. This standard is developed through a voluntary consensus process, overseen by a joint committee staffed by NSF employees, state regulatory officers, industry manufacturers, and consumers. Geomatrix obtained certification. Geomatrix alleges that competitors then began conspiring against T&D systems, questioning whether T&D systems should be entitled to certification and disparaging the efficacy of T&D systems. The alleged conspiracy affected Geomatrix’s business by preventing it from obtaining state regulatory approval, although its certification should have made it possible to do so. Ultimately, Geomatrix withdrew its NSF certification. NSF has not adopted a new standard; discussions remain ongoing.Geomatrix filed suit, alleging violations of the Sherman Act and the Lanham Act. The Sixth Circuit affirmed the dismissal of the suit. The defendants’ petitioning activity was immunized under the Noerr-Pennington doctrine. Geomatrix failed to show the proximate cause required for its unfair competition claims, and its promissory estoppel claims were based on statements that did not state a sufficiently definite promise. View "Geomatrix, LLC v. NSF International" on Justia Law